Loading [Contrib]/a11y/accessibility-menu.js
Review

Calpain inhibition as a possible new therapeutic target in multiple sclerosis

  • Multiple sclerosis (MS), the most common chronic autoimmune inflammatory disease of the central nervous system (CNS), is characterized by demyelination and neurodegeneration. In particular, neurodegeneration is a major factor in disease progression with neuronal death and irreversible axonal damage leading to disability. MS is manageable with current therapies that are directed towards immunomodulation but there are no available therapies for neuroprotection. The complex pathophysiology and heterogeneity of MS indicate that therapeutic agents should be directed to both the inflammatory and neurodegenerative arms of the disease. Activity of the Ca2+ activated protease calpain has been previously implicated in progression of MS and its primary animal model, experimental autoimmune encephalomyelitis (EAE). The effects of calpain inhibitors in EAE involve downregulation of Th1/Th17 inflammatory responses and promotion of regulatory T cells, overall leading to decreased inflammatory cell infiltration in CNS tissues. Furthermore, analysis of brains, spinal cords and optic nerves from EAE animals revealed decreases in axon degeneration, motor neuron and retinal ganglion cell death. This resulted in improved severity of paralysis and preservation of visual function. Taken together, the studies presented in this brief review suggest that use of calpain inhibitors in combination with an immunomodulatory agent may be a potential therapeutic strategy for MS and optic neuritis.

    Citation: Amena W. Smith, Swapan K. Ray, Arabinda Das, Kenkichi Nozaki, Baerbel Rohrer, Naren L. Banik. Calpain inhibition as a possible new therapeutic target in multiple sclerosis[J]. AIMS Molecular Science, 2017, 4(4): 446-462. doi: 10.3934/molsci.2017.4.446

    Related Papers:

    [1] Gaozhong Sun, Tongwei Zhao . Lung adenocarcinoma pathology stages related gene identification. Mathematical Biosciences and Engineering, 2020, 17(1): 737-746. doi: 10.3934/mbe.2020038
    [2] Kunpeng Li, Zepeng Wang, Yu Zhou, Sihai Li . Lung adenocarcinoma identification based on hybrid feature selections and attentional convolutional neural networks. Mathematical Biosciences and Engineering, 2024, 21(2): 2991-3015. doi: 10.3934/mbe.2024133
    [3] Yong Ding, Jian-Hong Liu . The signature lncRNAs associated with the lung adenocarcinoma patients prognosis. Mathematical Biosciences and Engineering, 2020, 17(2): 1593-1603. doi: 10.3934/mbe.2020083
    [4] Pingping Song, Jing Chen, Xu Zhang, Xiaofeng Yin . Construction of competitive endogenous RNA network related to circular RNA and prognostic nomogram model in lung adenocarcinoma. Mathematical Biosciences and Engineering, 2021, 18(6): 9806-9821. doi: 10.3934/mbe.2021481
    [5] Rafael Martínez-Fonseca, Cruz Vargas-De-León, Ramón Reyes-Carreto, Flaviano Godínez-Jaimes . Bayesian analysis of the effect of exosomes in a mouse xenograft model of chronic myeloid leukemia. Mathematical Biosciences and Engineering, 2023, 20(11): 19504-19526. doi: 10.3934/mbe.2023864
    [6] Xinwang Yan, Xiaowen Zhao, Qing Yan, Ye Wang, Chunling Zhang . Analysis of the role of METTL5 as a hub gene in lung adenocarcinoma based on a weighted gene co-expression network. Mathematical Biosciences and Engineering, 2021, 18(5): 6608-6619. doi: 10.3934/mbe.2021327
    [7] Ming Zhang, Yingying Zhou, Yanli Zhang . High Expression of TLR2 in the serum of patients with tuberculosis and lung cancer, and can promote the progression of lung cancer. Mathematical Biosciences and Engineering, 2020, 17(3): 1959-1972. doi: 10.3934/mbe.2020104
    [8] Bijiong Wang, Yaodong Tang, Biyun Yu, Di Gui, Hui Xu . Expression of autophagy-related factor p62 for lung cancer diagnosis and prognosis: A systematic review and meta-analysis. Mathematical Biosciences and Engineering, 2019, 16(6): 6805-6821. doi: 10.3934/mbe.2019340
    [9] Yingjian Yang, Wei Li, Yan Kang, Yingwei Guo, Kai Yang, Qiang Li, Yang Liu, Chaoran Yang, Rongchang Chen, Huai Chen, Xian Li, Lei Cheng . A novel lung radiomics feature for characterizing resting heart rate and COPD stage evolution based on radiomics feature combination strategy. Mathematical Biosciences and Engineering, 2022, 19(4): 4145-4165. doi: 10.3934/mbe.2022191
    [10] Chang Gong, Jennifer J. Linderman, Denise Kirschner . A population model capturing dynamics of tuberculosis granulomas predicts host infection outcomes. Mathematical Biosciences and Engineering, 2015, 12(3): 625-642. doi: 10.3934/mbe.2015.12.625
  • Multiple sclerosis (MS), the most common chronic autoimmune inflammatory disease of the central nervous system (CNS), is characterized by demyelination and neurodegeneration. In particular, neurodegeneration is a major factor in disease progression with neuronal death and irreversible axonal damage leading to disability. MS is manageable with current therapies that are directed towards immunomodulation but there are no available therapies for neuroprotection. The complex pathophysiology and heterogeneity of MS indicate that therapeutic agents should be directed to both the inflammatory and neurodegenerative arms of the disease. Activity of the Ca2+ activated protease calpain has been previously implicated in progression of MS and its primary animal model, experimental autoimmune encephalomyelitis (EAE). The effects of calpain inhibitors in EAE involve downregulation of Th1/Th17 inflammatory responses and promotion of regulatory T cells, overall leading to decreased inflammatory cell infiltration in CNS tissues. Furthermore, analysis of brains, spinal cords and optic nerves from EAE animals revealed decreases in axon degeneration, motor neuron and retinal ganglion cell death. This resulted in improved severity of paralysis and preservation of visual function. Taken together, the studies presented in this brief review suggest that use of calpain inhibitors in combination with an immunomodulatory agent may be a potential therapeutic strategy for MS and optic neuritis.


    Lung cancer is one of the common malignancies with the morbidity and mortality ranking top, about more than 1.8 million new cases with lung cancer are diagnosed and near 1.6 million patients die every year [1]. Among all cases suffering lung cancer, non-small cell lung cancer (NSCLC) accounts for 85% [2], with the main histologic phenotypes of adenocarcinoma, squamous-cell carcinoma and large cell carcinoma [3]. Therein, lung adenocarcinoma is the principal pathological pattern, nearly taking up 50% [4]. At present, radiotherapy, chemotherapy, surgery, immunotherapy and Chinese medicine are major curative options for patients suffering lung adenocarcinoma, and surgery remains the most effective approach. However, as patients always develop distant metastasis in an early stage with a five-year survival rate less than 15%, surgical is no more a good choice [5,6]. Therefore, the exploration on the molecular mechanism of lung adenocarcinoma invasion and metastasis in an early stage is of great importance for the development of novel diagnostic and therapeutic regimens.

    Exosome, an extracellular vesicle, was firstly reported by Taylor, et al. in 1979 and then verified in reticulocytes of mature mammals for the first time by Pan, et al. in 1985. Increasing evidence has shown that exosomes are essentially specific subcellular structures with important biological functions and specific bioactive substances like DNA, mRNA, ncRNA, protein, lipid, as well as other specific surface markers, such as CD63, CD81, Alix and Tsg101 [7]. Some studies suggested that there were two types of exosome: immune active exosomes involved in antigen presentation and co-stimulation, and the exosomes containing RNA and mediating genetic communication between cells [8,9,10]. As exosomes in body fluids originate from the corresponding tissues and organs, the composition of bioactive molecules in exosomes reflects the functional status of the corresponding tissues and organs. In addition, other studies have shown that exosomes, harboring abundant, stable, sensitive and specific biological information, are liquid biopsy specimens of relatively high application value [11], and play an important role in the regulation of immune response and tumor metastasis. Tumor-derived exosomes carry a variety of immunosuppressive signals, which can invalidate anti-tumor immune effectors and promote tumors to escape from epidemic control [12]. Besides, exogenous exosomes can induce metabolic reprogramming by restoring cancer cell respiration and inhibiting tumor growth [13]. With the continuous development of exosome purification, extraction and screening technology, it is promising to develop the application of exosomes in early cancer diagnosis, monitoring and prognosis evaluation [14].

    The purpose of this study is to investigate the changes on morphology and expression level of exosomes in peripheral blood of mice with lung adenocarcinoma at different stages during the tumorigenesis and development, which helps to the further application of exosomes in lung adenocarcinoma diagnosis and prognosis assessment.

    N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) (L/N: EVNGB-RH) was purchased from Tokyo Chemical Industry; Rotary Slicer (Type: RM2235) was from LEICA company; Water Bath-Slide Drier (Type: Tec 2500) was from Changzhou Haosilin Medical Instrument Co., Ltd.; Hematoxylin (Art. No: H9627; L/N: SLBN3249V) and Eosin (Art. No: E6003; L/N: 62R80915X) were both from Sigma; exosome extraction kit (Art. No: E1001) was from Geneseed Biotech Co., Ltd.; primary antibodies CD63, TSG101 and β-actin were all from Abcam, US; secondary antibodies Goat anti-Rabbit IgG and Goat anti-Mouse IgG were from Multi Sciences (Lianke) Biotech Co., Ltd.; enzyme-labeled instrument (SPECTRA max Plus 384) was from Molecular Devices company; electrophoresis system (Mini-Proten Tetra System) was from Bio-RAD company; maintenance feed was provided by Jiangsu Xietong Pharmaceutical Bio-engineering Co., Ltd. Execution Standard Number: GB14924.3-2010 Laboratory Animals-Nutrients for Formula Feeds.

    Fifty SPF KM mice (4 weeks old, weighing 18-22 g, female) were randomly divided into two groups: control group (n = 10) and lung adenocarcinoma model group (n = 40). Mice in the control group were fed normally with no drug treatment according to SPF requirement. After 28 weeks, the mice were executed and the indices were tested. Mice in the lung adenocarcinoma model group were fed for 28 weeks according to SPF requirement as well. Differently, they were subcutaneously injected (S.C.) with nitrosoguanidine once a week for 4 consecutive weeks from the beginning, 10 mice among which were executed at 4 appointed time points (14th week, 18th week, 24th week, 28th week), followed by indexes test. According to the literature reports, lung adenocarcinoma can be staged as precancerous (14th week), early (18th week), middle (22nd week) and advanced stages (28th week) from the first administration.

    Mice in the model group were allowed to acclimate for one week before model establishment. They were housed in a 65-75% relative humidified environment at 23 ℃ and had free access to food and drink. The establishment of model animals was conducted referring to Luo et al.'s study in 1992 [15]: MNNG (0.2 mL, 2.0 mg/mL) were injected into the mice back by S.C. every week for 4 consecutive weeks [A7-im]. Then the samples were collected and tested at the four appointed time points.

    The mice were anesthetized by intraperitoneal injection of 0.02 mL of ketamine solution (10 mg/mL). Cardiac puncture was performed for blood extraction. The neck skin was cut along the middle line to separate the trachea, which was then ligated at the end of deep inspiration to keep the lungs expanding. Subsequently, the lungs, liver and kidney were separated. Mice of the control group were also treated in the same way. Lung tumor of 0.5 mm was taken as the criterion for judgement of early lung adenocarcinoma in mice. Lung, liver and kidney were immersed in 4% formaldehyde solution for more than 24 hours, respectively. Ten tumor nodules were randomly selected and cut into tissue blocks of 3 mm thick. After dehydration, paraffin immersion, embedding, ultrathin sections (3 μm thick), tissue samples were stained with HE and blocked, followed by observed under a light microscope in many aspects, such as the histological type, location, size and margin of the tumors.

    Paraffin sections of mice lung tissues were dewaxed, rehydrated, and stained in hematoxylin dye solution at room temperature for 5 min. Tap water was utilized to wash the sections. Then, the sections were immersed in 1% hydrochloric acid alcohol solution for several seconds and rinsed by tap water until the tissues were back to blue. Subsequently, the sections were stained by Eosin for 3-5 min and washed in tap water again. After dehydration, clearing and sealing, the nuclei presented blue or purple blue, the cytoplasm was pink, and red blood cells showed bright red.

    Cardiac puncture was performed in mice in both model and control groups. Blood samples were collected and underwent anticoagulation with heparin. Thereafter, the blood was centrifuged at 4 ℃ for 20 min (2000 r/min). Upper plasma was taken out to 1.5 mL of RNase-free EP tube and stored at -80 ℃ for standby application. For better observation, blood from the 10 mice treated each time point was randomly divided into 5 groups. Exosome extraction reagent, Exoquick precipitation, was used to extract exosomes from the 0.5 mL of standby plasma following the instructions. After extraction, Transmission Electron Microscope (TEM) was applied to observe the morphology and size of exosomes. Western blot was sequentially conducted to detect the specific maker proteins of exosomes, including TSG101 and CD63.

    The prepared precipitate suspension of exosomes was firstly fixed with 2.5% glutaraldehyde and 1% citric acid, then dropped on a copper-loaded mesh and maintained at room temperature for 2 min. Liquid was absorbed from the side by filter paper, and the exosomes were negatively stained with 4% phosphotungstic acid solution for 2 min at room temperature. Then the dye solution was absorbed and the mesh was dried under incandescent light for about 10 min. Image was observed and photographed under a TEM.

    Proteins extracted from exosomes were concentrated by BCA method and quantitated using BCA quantitation kits with loading buffer. Then the proteins were separated by SDS-PAGE (150 g/L) and transferred onto nitrocellulose membrane (NC), which was sequentially blocked in 5% milk powder solution prepared by TBST for 2 hours. TBST was used to wash the membrane. Thereafter, the membrane was incubated with two primary antibodies (anti-mouse TSG101 and CD63, dilution at 1:5000 and 1:1000, respectively) at 4 ℃ for 12 hours, followed by HRP-labeled secondary antibodies (Goat anti-Rabbit IgG and Goat anti-Mouse IgG, both dilution at 1:5000) for 2 hours. Protein bands were visualized using colloidal gold kit according to the manufacturer’s protocols. Quantity One software was utilized to analyze the gray-scale values and the relative expression of proteins were calculated. The experiment was repeated 3 times.

    Variance analysis and statistical test were performed to analyze means of multiple groups with GraphPad Prism software. The count data in Table 1 were presented in the form of mean value ± standard deviation. Comparison of measurement data was performed by t test. All experiments were duplicated at least three times. A P-value less than 0.05 was statistically significant.

    Table 1.  Statistic number of tumor in lung tissue section of each mouse.
    Group Number
    Control Group 0
    Model-14w Group 4.20 ± 2.59
    Model-18w Group 8.80 ± 6.61
    Model-24w Group 6.40 ± 3.21
    Model-28w Group 10.00 ± 5.64

     | Show Table
    DownLoad: CSV

    As shown in Figure 1, lung tissues in the control group presented normal structures, with no obvious lesions except local thickening of alveolar wall in individual samples. While in the model groups, pulmonary masses were obvious at 14 W and 18 W and clearly distinguished with the surrounding areas. In addition, masses in some samples showed gland-like growth trend, finally proceeding to lung adenocarcinoma. From the time of 24 W, the adenoid proliferation of cancer cells were more obvious than that at the last 2 time points, showing irregular shapes and unclear boundaries. Moreover, as shown in Table 1, the number of pulmonary masses in each model group was increased significantly relative to that in the control group (P < 0.05). Collectively, the results showed that the lung adenocarcinoma model mice were successfully established.

    Figure 1.  HE staining results of lung tissue pathological changes.

    TEM was used to observe the morphology and structure of exosomes in the control group and model groups. As exhibited in Figure 2, membranes of exosomes showed clear structures, presenting as saucer or concave hemisphere. Exosomes with 50-200 nm size were considered successfully extracted.

    Figure 2.  Morphology and structure of exosomes observed by TEM.

    Western blot was conducted to detect the protein levels of CD63 and TSG101 in the control group and model groups. As shown in Figure 3, with the extension of modeling time, the protein levels of CD63 in the model groups were increased gradually relative to that in the control group, and the highest level was found in the model group at 28 W with significant difference (P < 0.01). This finding revealed that there was strong association between the different stages of lung adenocarcinoma and the expression level of exosomes in serum. Similarly, TSG101 in the model groups exhibited remarkedly increased protein level by comparison with that in the control group (P < 0.05). However, there was no significant correlation observed.

    Figure 3.  Expression of CD63 and TSG101 detected by Western blot. (A) Electrophoretic band graph of CD63 and TSG101; (B) Expression of CD63; (C) Expression of TSG101. (“*” means P < 0.05, “**” means P < 0.01).

    In recent years, the study on exosomes in disease diagnosis and prognosis evaluation has become a hotspot. So far, exosomes from various tumors have been researched, including colorectal cancer, breast cancer, prostate cancer and pancreatic cancer. Exosomes have been used as potential biomarkers and therapeutic targets for cancer. In 2016, the first exosome-based cancer diagnostic product came into the market [16], marking the new progress of exosome-based therapy for cancer. Research based on exosomes and their related components may bring new hope for the treatment of cancer patients.

    Some scholars have proposed the mechanism of exosomes involved in tumorigenesis, development and metastasis: tumor exosomes (TEX) contain a large number of active molecules that can promote tumor cell growth, invasion and metastasis, such as proteins, mRNAs and miRNAs. Exosomes can targeted transfer these active substances to mesenchymal cells, endothelial cells, inflammatory cells and immune cells, which were then "domesticated" to produce various factors conducive to the tumor proliferation, invasion and migration, consequently allowing for the formation of "pre-metastasis microenvironment" of tumors [17]. The increase of exosomes can promote the proliferation, metastasis and invasion of cancer cells, leading to deterioration of the disease.

    In this project, lung adenocarcinoma model mice were constructed by subcutaneous injection of nitrosoguanidine. HE staining was applied to observe the pathological changes of lung tissues, thereby verifying the success of the mouse model establishment. TEM was utilized for the observation of exosomes morphology in serum at different stages of the lung adenocarcinoma in mice (precancerous stage, early stage, middle stage and advanced stage), finding that the exosomes membrane had clear structures and presented as saucer or concave hemisphere. In addition, with the progression of lung cancer in mice, the number of exosomes was increased, which indicated a closely correlation between the exosomes and the tumorigenesis as well as development. Moreover, Western blot was employed to test specific proteins (TSG101 and CD63) of exosome, finding that with the progress of lung cancer, CD63 in the model groups had significantly elevated protein level relative to that in the control group, which again suggested that exosomes might be involved in the regulation of lung cancer progress. However, despite the similar trend of TSG101 expression in the mouse models, the result was not sufficient to reflect the correlation between cancer development stages and exosome level, thus further experimental verification should be carried out. Zhang Y, et al. [18] reported that the protein levels of exosome markers, CD62P and CD63, in peripheral blood of lung cancer patients were significantly higher than those of healthy people. Furthermore, Liu F, et al. [19] suggested that compared with normal pulmonary epithelial cells, the expression of TSG101 mRNA in lung cancer cell lines was much higher. Taken together, these findings reveal that the up-regulation of exosomes level in lung cancer can be used as a platelet-like diagnostic index so as to provide a new way for the diagnosis of lung cancer.

    This study primary verified a strong association between the development of lung adenocarcinoma in mice and the level of exosomes in serum through the detection of exosomes morphology and specific proteins expression levels. However, there are some limitations in this experiment. Although the expression of TSG101 showed increased trend as CD63, it could not reflect such association between tumor and exosome. Therefore, more exosome-related markers should be selected in subsequent experiments for further verification. Although the specific mechanism of exosomes on the occurrence and development of lung adenocarcinoma had not been further studied, this study provides possibility for the diagnosis of pathological staging of lung adenocarcinoma by exosomes.

    This study was supported by Public Welfare Technology Application on Animal Experiment of Science and Technology Agency in Zhejiang Province (2017C37103).

    The authors declare they have no conflict of interest.

    [1] Dargahi N, Katsara M, Tselios T, et al. (2017) Multiple Sclerosis: Immunopathology and Treatment Update. Brain Sci 7: 78. doi: 10.3390/brainsci7070078
    [2] Confavreux C, Vukusic S (2014) The clinical course of multiple sclerosis. Handb Clin Neurol 122: 343-369. doi: 10.1016/B978-0-444-52001-2.00014-5
    [3] Confavreux C, Vukusic S, Moreau T, et al. (2001) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343: 1430-1438.
    [4] Kinzel S, Weber MS (2016) B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence. Cns Drug 30: 1137-1148. doi: 10.1007/s40263-016-0396-6
    [5] Fernando NT, Koch M, Rothrock C, et al. (2008) Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res 14: 1529-1539. doi: 10.1158/1078-0432.CCR-07-4126
    [6] Rottlaender A, Kuerten S. (2015) Stepchild or Prodigy? Neuroprotection in Multiple Sclerosis (MS) Research. Int J Mol Sci 16: 14850-14865.
    [7] Popescu V, Agosta F, Hulst HE, et al. (2013) Brain atrophy and lesion load predict long term disability in multiple sclerosis. J Neurol Neurosur Psychiatr 84: 1082-1091. doi: 10.1136/jnnp-2012-304094
    [8] Vickers JC, King AE, Woodhouse A, et al. (2009) Axonopathy and cytoskeletal disruption in degenerative diseases of the central nervous system. Brain Res Bull 80: 217-223. doi: 10.1016/j.brainresbull.2009.08.004
    [9] Mentis AA, Dardiotis E, Grigoriadis N, et al. (2017) Viruses and Multiple Sclerosis: From Mechanisms and Pathways to Translational Research Opportunities. Mol neurobiol 54: 3911-3923. doi: 10.1007/s12035-017-0530-6
    [10] Berer K, Krishnamoorthy G (2014) Microbial view of central nervous system autoimmunity. FEBS lett 588: 4207-4213. doi: 10.1016/j.febslet.2014.04.007
    [11] Geginat J, Paroni M, Pagani M, et al. (2017) The Enigmatic Role of Viruses in Multiple Sclerosis: Molecular Mimicry or Disturbed Immune Surveillance? Trend in Immunol 38: 498-512. doi: 10.1016/j.it.2017.04.006
    [12] Brownlee WJ, Miller DH (2014) Clinically isolated syndromes and the relationship to multiple sclerosis. J Clin Neurosci 21: 2065-2071. doi: 10.1016/j.jocn.2014.02.026
    [13] Rocca MA, Preziosa P, Mesaros S, et al. (2016) Clinically Isolated Syndrome Suggestive of Multiple Sclerosis: Dynamic Patterns of Gray and White Matter Changes-A 2-year MR Imaging Study. Radiology 278: 841-853. doi: 10.1148/radiol.2015150532
    [14] Klaver R, Popescu V, Voorn P, et al. (2015) Neuronal and axonal loss in normal-appearing gray matter and subpial lesions in multiple sclerosis. J Neuropathol Exp Neurol 74: 453-458. doi: 10.1097/NEN.0000000000000189
    [15] De SN, Giorgio A, Battaglini M, et al. (2010) Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 74: 1868-1876. doi: 10.1212/WNL.0b013e3181e24136
    [16] Alonso A, Hernán MA (2008) Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 71: 129-135. doi: 10.1212/01.wnl.0000316802.35974.34
    [17] Rojas JI, Patrucco L, Miguez J, et al. (2016) Brain atrophy in multiple sclerosis: therapeutic, cognitive and clinical impact. Arq Neuro-Psiquiat 74: 235-243. doi: 10.1590/0004-282X20160015
    [18] Rojas JI, Patrucco L, Besada C, et al. (2010) [Brain atrophy in clinically isolated syndrome]. Neurología 25: 430-434.
    [19] Tawse KL, Gobuty M, Mendoza-Santiesteban C (2014) Optical coherence tomography shows retinal abnormalities associated with optic nerve disease. Br J Ophthalmol 98: ii30-3. doi: 10.1136/bjophthalmol-2013-304301
    [20] You Y, Gupta VK, Li JC, et al. (2013) Optic neuropathies: characteristic features and mechanisms of retinal ganglion cell loss. Rev Neurosci 24: 301-321.
    [21] Namekata K, Kimura A, Kawamura K, et al. (2013) Dock3 attenuates neural cell death due to NMDA neurotoxicity and oxidative stress in a mouse model of normal tension glaucoma. Cell Death Diff 20: 1250-1256. doi: 10.1038/cdd.2013.91
    [22] Burkholder BM, Osborne B, Loguidice MJ, et al. (2009) Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis. Arch Neurol 66: 1366.
    [23] Frohman EM, Dwyer MG, Frohman T, et al. (2009) Relationship of optic nerve and brain conventional and non-conventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: a pilot study. J Neurol Sci 282: 96-105. doi: 10.1016/j.jns.2009.04.010
    [24] Pineles SL, Birch EE, Talman LS, et al. (2011) One eye or two: a comparison of binocular and monocular low-contrast acuity testing in multiple sclerosis. Am J Ophthalmol 152: 133-140. doi: 10.1016/j.ajo.2011.01.023
    [25] Martin R, Mcfarland HF, Mcfarlin DE (1992) Immunological aspects of demyelinating diseases. Annu Rev Immunol 10: 153. doi: 10.1146/annurev.iy.10.040192.001101
    [26] Hobom M, Storch MK, Weissert R, et al. (2004) Mechanisms and time course of neuronal degeneration in experimental autoimmune encephalomyelitis. Brain Pathol 14: 148-157. doi: 10.1111/j.1750-3639.2004.tb00047.x
    [27] Croxford AL, Kurschus FC, Waisman A (2011) Mouse models for multiple sclerosis: historical facts and future implications. Biochim Biophys Acta 1812: 177-183. doi: 10.1016/j.bbadis.2010.06.010
    [28] Shields DC, Banik NL (1999) Pathophysiological role of calpain in experimental demyelination. J Neurosci Res 55: 533-541. doi: 10.1002/(SICI)1097-4547(19990301)55:5<533::AID-JNR1>3.0.CO;2-8
    [29] Hassen GW, Feliberti J, Kesner L, et al. (2006) A novel calpain inhibitor for the treatment of acute experimental autoimmune encephalomyelitis. J Neuroimmunol 180: 135-146. doi: 10.1016/j.jneuroim.2006.08.005
    [30] Guyton MK, Das A, Samantaray S, et al. (2010) Calpeptin attenuated inflammation, cell death, and axonal damage in animal model of multiple sclerosis. J Neurosci Res 88: 2398-2408.
    [31] Kobeissy FH. (2015) Brain Neurotrauma: Molecular, Neuropsychological, and Rehabilitation Aspects. Crc Press.
    [32] Sun JF, Yang HL, Huang YH, et al. (2017) CaSR and calpain contribute to the ischemia reperfusion injury of spinal cord. Neurosci lett 646: 49-55. doi: 10.1016/j.neulet.2017.03.009
    [33] Samantaray S, Knaryan VH, Shields DC, et al. (2013) Critical role of calpain in spinal cord degeneration in Parkinson's disease. J Neurochem 127: 880. doi: 10.1111/jnc.12374
    [34] Siklos M, Benaissa M, Thatcher GRJ (2015) Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors. Acta pharmaceutica Sinica B 5: 506-519.
    [35] Smith AW, Rohrer B, Wheless L, et al. (2016) Calpain inhibition reduces structural and functional impairment of retinal ganglion cells in experimental optic neuritis. J Neurochem 139: 270-284. doi: 10.1111/jnc.13770
    [36] Ono Y, Sorimachi H (2012) Calpains: an elaborate proteolytic system. Biochim Biophys Acta 1824: 224-236. doi: 10.1016/j.bbapap.2011.08.005
    [37] Pietrobon D, Di VF, Pozzan T (1990) Structural and functional aspects of calcium homeostasis in eukaryotic cells. Eur J Biochem 193: 599-622. doi: 10.1111/j.1432-1033.1990.tb19378.x
    [38] Wu HY, Tomizawa K, Matsui H (2007) Calpain-calcineurin signaling in the pathogenesis of calcium-dependent disorder. Acta Medica Okayama 61: 123-137.
    [39] Diaz-Sanchez M, Williams K, Deluca GC, et al. (2006) Protein co-expression with axonal injury in multiple sclerosis plaques. Acta Neuropathol 111: 289. doi: 10.1007/s00401-006-0045-0
    [40] Yan F, Sun W, Shi Y, et al. (2009) Glutamate excitotoxicity inflicts paranodal myelin splitting and retraction. Plos One 4: e6705. doi: 10.1371/journal.pone.0006705
    [41] Banik NL, Chou CH, Deibler GE, et al. (1994) Peptide bond specificity of calpain: proteolysis of human myelin basic protein. J Neurosci Res 37: 489-496. doi: 10.1002/jnr.490370408
    [42] Howe CL, Lafrancecorey RG, Mirchia K, et al. (2016) Neuroprotection mediated by inhibition of calpain during acute viral encephalitis. Sci Rep 6: 28699. doi: 10.1038/srep28699
    [43] Machado VM, Morte MI, Carreira BP, et al. (2015) Involvement of calpains in adult neurogenesis: implications for stroke. Front Cell Neurosci 9: 22.
    [44] Knaryan VH, Samantaray S, Park S, et al. (2014) SNJ-1945, a calpain inhibitor, protects SH-SY5Y cells against MPP(+) and rotenone. J Neurochem 130: 280-290. doi: 10.1111/jnc.12629
    [45] Donkor IO (2000) A survey of calpain inhibitors. Curr Med Chem 7: 1171-1181. doi: 10.2174/0929867003374129
    [46] Shirasaki Y, Miyashita H, Yamaguchi M, et al. (2005) Exploration of orally available calpain inhibitors: peptidyl alpha-ketoamides containing an amphiphile at P3 site. Bioorg Med Chem 13: 4473-4484. doi: 10.1016/j.bmc.2005.04.059
    [47] Donkor IO, Zheng X, Miller DD (2000) Synthesis and calpain inhibitory activity of alpha-ketoamides with 2,3-methanoleucine stereoisomers at the P2 position. Bioorg Med Chem Lett 10: 2497-2500. doi: 10.1016/S0960-894X(00)00518-7
    [48] Carragher NO (2006) Calpain inhibition: a therapeutic strategy targeting multiple disease states. Curr Pharm Design 12: 615-638. doi: 10.2174/138161206775474314
    [49] Barrett AJ, Kembhavi AA, Brown MA, et al. (1982) L-trans-Epoxysuccinyl-leucylamido (4-guanidino) butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem J 201: 189-198. doi: 10.1042/bj2010189
    [50] Saido TC, Sorimachi H, Suzuki K (1994) Calpain: new perspectives in molecular diversity and physiological-pathological involvement. FASEB J 8: 814-822.
    [51] Podbielska M, Das A, Smith AW, et al. (2016) Neuron-microglia interaction induced bi-directional cytotoxicity associated with calpain activation. J Neurochem 139: 440-455. doi: 10.1111/jnc.13774
    [52] Xiao T, Zhang Y, Wang Y, et al. (2013) Activation of an apoptotic signal transduction pathway involved in the upregulation of calpain and apoptosis-inducing factor in aldosterone-induced primary cultured cardiomyocytes. Food Chem Toxicol 53: 364-370. doi: 10.1016/j.fct.2012.12.022
    [53] Imai T, Kosuge Y, Endo-Umeda K, et al. (2014) Protective effect of S-allyl-L-cysteine against endoplasmic reticulum stress-induced neuronal death is mediated by inhibition of calpain. Amino Acids 46: 385-393. doi: 10.1007/s00726-013-1628-4
    [54] Li H, Zhang N, Sun G, et al. (2013) Inhibition of the group I mGluRs reduces acute brain damage and improves long-term histological outcomes after photothrombosis-induced ischaemia. ASN Neuro 5: 195.
    [55] Ray SK, Neuberger TJ, Deadwyler G, et al. (2002) Calpain and calpastatin expression in primary oligodendrocyte culture: preferential localization of membrane calpain in cell processes. J Neurosci Res 70: 561-569. doi: 10.1002/jnr.10414
    [56] Das A, Garner DP, Del Re AM, et al. (2006) Calpeptin provides functional neuroprotection to rat retinal ganglion cells following Ca2+ influx. Brain Res 1084: 146-157. doi: 10.1016/j.brainres.2006.02.051
    [57] Guyton MK, Brahmachari S, Das A, et al. (2009) Inhibition of calpain attenuates encephalitogenicity of MBP-specific T cells. J Neurochem 110: 1895-1907. doi: 10.1111/j.1471-4159.2009.06287.x
    [58] Guyton MK, Das A, Samantaray S, et al. (2010) Calpeptin attenuated inflammation, cell death, and axonal damage in animal model of multiple sclerosis. J Neurosci Res 88: 2398-2408.
    [59] Neffe AT, Abell AD (2005) Developments in the design and synthesis of calpain inhibitors. Curr Opin Drug Discov Develop 8: 684-700.
    [60] Das A, Sribnick EA, Wingrave JM, et al. (2005) Calpain activation in apoptosis of ventral spinal cord 4.1 (VSC4.1) motoneurons exposed to glutamate: calpain inhibition provides functional neuroprotection. J Neurosci Res 81: 551-562.
    [61] Sharma A1 (2007) Sustained elevation of intracellular cGMP causes oxidative stress triggering calpain-mediated apoptosis in photoreceptor degeneration. Curr Eye Res 32: 259-269. doi: 10.1080/02713680601161238
    [62] Min Y, Zhu W, Zheng X, et al. (2016) Effect of glutamate on lysosomal membrane permeabilization in primary cultured cortical neurons. Mol Med Rep 13: 2499-2505. doi: 10.3892/mmr.2016.4819
    [63] Shirasaki Y, Yamaguchi MH (2006) Retinal penetration of calpain inhibitors in rats after oral administration. J Ocul Pharmacol Ther 22: 417-424. doi: 10.1089/jop.2006.22.417
    [64] Koumura A, Nonaka Y, Hyakkoku K, et al. (2008). A novel calpain inhibitor, ((1S)-1((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-met hylbutyl) carbamic acid 5-methoxy-3-oxapentyl ester, protects neuronal cells from cerebral ischemia-induced damage in mice. Neurosci 157: 309-318. doi: 10.1016/j.neuroscience.2008.09.007
    [65] Nakajima E, Hammond KB, Rosales JL, et al. (2011) Calpain, not caspase, is the causative protease for hypoxic damage in cultured monkey retinal cells. Invest Ophthalmol Vis Sci 52: 7059-7067. doi: 10.1167/iovs.11-7497
    [66] Trager N, Butler JT, Haque A, et al. (2013) The Involvement of Calpain in CD4+ T Helper Cell Bias in Multple Sclerosis. J Clin Cell Iimmunol 4: 1000153.
    [67] Surh YJ, Chun KS, Cha HH, et al. (2001) Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res s480-481: 243-268.
    [68] Potz BA, Sabe AA, Elmadhun NY, et al. (2017) Calpain inhibition decreases inflammatory protein expression in vessel walls in a model of chronic myocardial ischemia. Surgery 161: 1394-1404. doi: 10.1016/j.surg.2016.11.009
    [69] Butler JT, Samantaray S, Beeson CC, et al. (2009) Involvement of calpain in the process of Jurkat T cell chemotaxis. J Neurosci Res 87: 626-635. doi: 10.1002/jnr.21882
    [70] Mikosik A, Jasiulewicz A, Daca A, et al. (2016) Roles of calpain-calpastatin system (CCS) in human T cell activation. Oncotarget 7: 76479-76495.
    [71] Moretti D, Del BB, Allavena G, et al. (2014) Calpains and cancer: friends or enemies? Arch Biochem Biophys 564: 26-36. doi: 10.1016/j.abb.2014.09.018
    [72] Deshpande RV, Goust JM, Hogan EL, et al. (1995) Calpain secreted by activated human lymphoid cells degrades myelin. J Neurosci Res 42: 259-265. doi: 10.1002/jnr.490420214
    [73] Jantzie LL, Winer JL, Corbett CJ, et al. (2016) Erythropoietin Modulates Cerebral and Serum Degradation Products from Excess Calpain Activation following Prenatal Hypoxia-Ischemia. Dev Neurosci 38: 15-26. doi: 10.1159/000441024
    [74] Guyton MK, Sribnick EA, Ray SK, et al. (2005) A role for calpain in optic neuritis. Ann NY Acad Sci 1053: 48-54. doi: 10.1196/annals.1344.005
    [75] Cerghet M, Skoff RP, Bessert D, et al (2006) Proliferation and death of oligodendrocytes and myelin proteins are differentially regulated in male and female rodents. J Neurosci 26: 1439-1447. doi: 10.1523/JNEUROSCI.2219-05.2006
    [76] Ding ZJ, Chen X, Tang XX, et al. (2015) Calpain inhibitor PD150606 attenuates glutamate induced spiral ganglion neuron apoptosis through apoptosis inducing factor pathway in vitro. PLoS One 10: e0123130. doi: 10.1371/journal.pone.0123130
    [77] Das A, Guyton MK, Matzelle DD, et al. (2008) Time-dependent increases in protease activities for neuronal apoptosis in spinal cords of Lewis rats during development of acute experimental autoimmune encephalomyelitis. J Neurosci Res 86: 2992-3001. doi: 10.1002/jnr.21737
    [78] Vosler PS, Brennan CS, Chen J (2008) Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. Mol Neurobiol 38: 78-100. doi: 10.1007/s12035-008-8036-x
    [79] Schaecher K, Goust JM, Banik NL (2004) The effects of calpain inhibition on IkB alpha degradation after activation of PBMCs: identification of the calpain cleavage sites. Neurochem Res 29: 1443-1451. doi: 10.1023/B:NERE.0000026410.56000.dd
    [80] Gerondakis S, Grumont R, Rourke I, et al. (1998) The regulation and roles of Rel/NF-kappa B transcription factors during lymphocyte activation. Curr Opin Immunol 10: 353-359. doi: 10.1016/S0952-7915(98)80175-1
    [81] Miyazaki T, Taketomi Y, Saito Y, et al. (2015) Calpastatin counteracts pathological angiogenesis by inhibiting suppressor of cytokine signaling 3 degradation in vascular endothelial cells. Circ Res 116: 1170-1181. doi: 10.1161/CIRCRESAHA.116.305363
    [82] Datta R, Naura AS, Zerfaoui M, et al. (2011) PARP-1 deficiency blocks IL-5 expression through calpain-dependent degradation of STAT-6 in a murine asthma model. Allergy 66: 853-861. doi: 10.1111/j.1398-9995.2011.02549.x
    [83] Tahvanainen J, Kallonen T, Lähteenmäki H, et al. (2009) PRELI is a mitochondrial regulator of human primary T-helper cell apoptosis, STAT6, and Th2-cell differentiation. Blood 113: 1268-1277. doi: 10.1182/blood-2008-07-166553
    [84] Hendry L, John S (2004) Regulation of STAT signalling by proteolytic processing. Eur J Biochem 271: 4613-4620. doi: 10.1111/j.1432-1033.2004.04424.x
    [85] Svensson L, Mcdowall A, Giles K M, et al. (2010) Calpain 2 controls turnover of LFA-1 adhesions on migrating T lymphocytes. PLoS One 5: e15090. doi: 10.1371/journal.pone.0015090
    [86] Stewart MP, Mcdowall A, Hogg N (1998) LFA-1-mediated adhesion is regulated by cytoskeletal restraint and by a Ca2+-dependent protease, calpain. J cell Biol 140: 699-707. doi: 10.1083/jcb.140.3.699
    [87] Soede RD, Driessens MH, Ruulsvan SL, et al. (1999) LFA-1 to LFA-1 signals involve zeta-associated protein-70 (ZAP-70) tyrosine kinase: relevance for invasion and migration of a T cell hybridoma. J Immunol 163: 4253-4261.
    [88] Engelhard VH, Altrich-Vanlith M, Ostankovitch M, et al. (2006) Post-translational modifications of naturally processed MHC-binding epitopes. Curr Opin Immunol 18: 92-97. doi: 10.1016/j.coi.2005.11.015
    [89] Imam SA, Guyton MK, Haque A, et al. (2007) Increased calpain correlates with Th1 cytokine profile in PBMCs from MS patients. J Neuroimmunol 190: 139-145. doi: 10.1016/j.jneuroim.2007.07.016
    [90] Zhang Z, Huang Z, Dai H, et al. (2015) Therapeutic Efficacy of E-64-d, a Selective Calpain Inhibitor, in Experimental Acute Spinal Cord Injury. BioMed Res Int: 134242.
    [91] Posmantur R, Hayes RL, Dixon CE, et al. (1994) Neurofilament 68 and neurofilament 200 protein levels decrease after traumatic brain injury. J Neurotrauma 11: 533-545. doi: 10.1089/neu.1994.11.533
    [92] Zhang JN, Michel U, Lenz C, et al. (2016) Calpain-mediated cleavage of collapsin response mediator protein-2 drives acute axonal degeneration. Sci Rep 6: 37050. doi: 10.1038/srep37050
    [93] Wilson GN, Smith MA, Inman DM, et al. (2016) Early Cytoskeletal Protein Modifications Precede Overt Structural Degeneration in the DBA/2J Mouse Model of Glaucoma. Front Neurosci 10: 494.
    [94] Saito K, Elce JS, Hamos E, et al. (1993) Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci USA 90: 2628-2632. doi: 10.1073/pnas.90.7.2628
    [95] Dowling P, Husar W, Menonna J, et al. (1997) Cell death and birth in multiple sclerosis brain. J Neurol Sci 149: 1-11. doi: 10.1016/S0022-510X(97)05213-1
    [96] Gerónimoolvera C, Montiel T, Rinconheredia R, et al. (2017) Autophagy fails to prevent glucose deprivation/glucose reintroduction-induced neuronal death due to calpain-mediated lysosomal dysfunction in cortical neurons. Cell Death Disease 8: e2911. doi: 10.1038/cddis.2017.299
    [97] Sharma AK, Rohrer B (2017) Calcium-induced calpain mediates apoptosis via caspase-3 in a mouse photoreceptor cell line. J Biol Chem 292: 13186. doi: 10.1074/jbc.A117.401037
    [98] Pitt D, Werner P, Raine CS (2000) Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 6: 67-70. doi: 10.1038/71555
    [99] Shields DC, Banik NL (1999) A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. Proc Natl Acad Sci USA 96: 11486-11491. doi: 10.1073/pnas.96.20.11486
    [100] Zhang ZW, Qin XY, Che FY, et al. (2015) Effects of beta 2 adrenergic agonists on axonal injury and mitochondrial metabolism in experimental autoimmune encephalomyelitis rats. Genetics and molecular research: GMR 14: 13572-13581. doi: 10.4238/2015.October.28.17
    [101] Kivisäkk P, Mahad DJ, Callahan MK, et al. (2003) Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci USA 100: 8389-8394. doi: 10.1073/pnas.1433000100
    [102] Lassmann H, Ransohoff RM (2004) The CD4-Th1 model for multiple sclerosis: a critical [correction of crucial] re-appraisal. Trends Immunol 25: 132-137. doi: 10.1016/j.it.2004.01.007
    [103] Dhib S (2003) Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype. J Neuroimmunol 140: 163-171. doi: 10.1016/S0165-5728(03)00170-X
    [104] Issazadeh S, Mustafa M, Ljungdahl A, et al. (1995) Interferon gamma, interleukin 4 and transforming growth factor beta in experimental autoimmune encephalomyelitis in Lewis rats: dynamics of cellular mRNA expression in the central nervous system and lymphoid cells. J Neurosci Res 40: 579-590. doi: 10.1002/jnr.490400503
    [105] Kennedy MK, Torrance DS, Picha KS, et al. (1992) Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol 149: 2496.
    [106] Nishihara M, Ogura H, Ueda N, et al. (2007) IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state. Int Immunol 19: 695-702. doi: 10.1093/intimm/dxm045
    [107] Immunology N (2005) Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6: 1123-1132. doi: 10.1038/ni1254
    [108] Park H, Li Z, Yang XO, et al. (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6: 1133-1141. doi: 10.1038/ni1261
    [109] Passos GRD, Sato DK, Becker J, et al. (2016) Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications. Mediat Inflamm 2016: 1-11.
    [110] Zahra S, Rozita D, Masoumeh B, et al. (2016) Differential Frequency of CD8+ T Cell Subsets in Multiple Sclerosis Patients with Various Clinical Patterns. PLoS One 11: e0159565. doi: 10.1371/journal.pone.0159565
    [111] Kebir H, Ifergan I, Alvarez JI, et al. (2009) Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann Neurol 66: 390-402. doi: 10.1002/ana.21748
    [112] Thackray SJ, Mowat CG, Chapman SK (2008) Exploring the mechanism of tryptophan 2,3-dioxygenase. Biochem Soc Trans 36: 1120-1123. doi: 10.1042/BST0361120
    [113] Stone TW, Darlington LG (2002) Endogenous kynurenines as targets for drug discovery and development. Nat Rev 1: 609-620.
    [114] Munn DH, Mellor AL (2007) Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 117: 1147-1154. doi: 10.1172/JCI31178
    [115] Fallarino F, Grohmann U, You S, et al. (2006) The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 176: 6752-6761. doi: 10.4049/jimmunol.176.11.6752
    [116] Mackenzie CR, Heseler K, Müller A, et al. (2007) Role of indoleamine 2,3-dioxygenase in antimicrobial defence and immuno-regulation: tryptophan depletion versus production of toxic kynurenines. Curr Drug Metab 8: 237-244. doi: 10.2174/138920007780362518
    [117] Mancuso R, Hernis A, Agostini S, et al. (2015) Indoleamine 2,3 Dioxygenase (IDO) Expression and Activity in Relapsing-Remitting Multiple Sclerosis. Plos One 10: e0130715. doi: 10.1371/journal.pone.0130715
    [118] Sousa DA, Porto WF, Silva MZ, et al. (2016) Influence of Cysteine and Tryptophan Substitution on DNA-Binding Activity on Maize α-Hairpinin Antimicrobial Peptide. Molecules 21: 1062. doi: 10.3390/molecules21081062
    [119] Smith AW, Doonan BP, Tyor WR, et al. (2011) Regulation of Th1/Th17 cytokines and IDO gene expression by inhibition of calpain in PBMCs from MS patients. J Neuroimmunol 232: 179-185. doi: 10.1016/j.jneuroim.2010.09.030
    [120] Cilingir V, Batur M, Bulut MD, et al. (2017) The association between retinal nerve fibre layer thickness and corpus callosum index in different clinical subtypes of multiple sclerosis. Neurol Sci 38: 1223-1232. doi: 10.1007/s10072-017-2947-0
    [121] Britze J, Pihljensen G, Frederiksen JL (2017) Retinal ganglion cell analysis in multiple sclerosis and optic neuritis: a systematic review and meta-analysis. J Neurol 264: 1837-1853. doi: 10.1007/s00415-017-8531-y
    [122] Mowry EM, Loguidice MJ, Daniels AB, et al. (2009) Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity. J Neurol Neurosurg Psychia 80: 767-772. doi: 10.1136/jnnp.2008.165449
    [123] Mackay DD (2015) Should patients with optic neuritis be treated with steroids? Curr Opin Ophthalmol 26: 439-444. doi: 10.1097/ICU.0000000000000197
    [124] Dimitriu C, Bach M, Lagrèze WA, et al. (2008) Methylprednisolone fails to preserve retinal ganglion cells and visual function after ocular ischemia in rats. Invest Ophthalmol Vis Sci 49: 5003-5007. doi: 10.1167/iovs.08-1869
    [125] Das A, Guyton MK, Smith A, et al. (2013) Calpain inhibitor attenuated optic nerve damage in acute optic neuritis in rats. J Neurochem 124: 133-143. doi: 10.1111/jnc.12064
    [126] Shields DC, Tyor WR, Deibler GE, et al. (1998) Increased calpain expression in experimental demyelinating optic neuritis: an immunocytochemical study. Brain Res 784: 299-304. doi: 10.1016/S0006-8993(97)01381-4
    [127] Hoffmann DB, Williams SK, Jovana B, et al. (2013) Calcium influx and calpain activation mediate preclinical retinal neurodegeneration in autoimmune optic neuritis. J Neuropathol Exp Neurol 72: 745-757. doi: 10.1097/NEN.0b013e31829c7370
    [128] Shimazawa M, Suemori S, Inokuchi Y, et al. (2010) A novel calpain inhibitor, ((1S)-1-((((1S)-1-Benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester (SNJ-1945), reduces murine retinal cell death in vitro and in vivo. J Pharm Exp Ther 332: 380-387. doi: 10.1124/jpet.109.156612
    [129] Imai S, Shimazawa M, Nakanishi T, et al. (2010) Calpain inhibitor protects cells against light-induced retinal degeneration. J Pharm Exp Ther 335: 645-652. doi: 10.1124/jpet.110.171298
    [130] Yokoyama Y, Maruyama K, Yamamoto K, et al. (2014) The role of calpain in an in vivo model of oxidative stress-induced retinal ganglion cell damage. Biochem Biophys Res Comm 451: 510-515. doi: 10.1016/j.bbrc.2014.08.009
    [131] Wang Y, Liu Y, Lopez D, et al. (2017) Protection against TBI-induced neuronal death with post-treatment with a selective calpain-2 inhibitor in mice. J Neurotrauma.
    [132] Tsuda S, Tanaka Y, Kunikata H, et al. (2016) Real-time imaging of RGC death with a cell-impermeable nucleic acid dyeing compound after optic nerve crush in a murine model. Exp Eye Res 146: 179-188. doi: 10.1016/j.exer.2016.03.017
    [133] Ryu M, Yasuda M, Shi D, et al. (2012) Critical role of calpain in axonal damage-induced retinal ganglion cell death. J Neurosci Res 90: 802-815. doi: 10.1002/jnr.22800
    [134] Nemeth CL, Drummond GT, Mishra MK, et al. (2017) Uptake of dendrimer-drug by different cell types in the hippocampus after hypoxic-ischemic insult in neonatal mice: Effects of injury, microglial activation and hypothermia. Nanomedicine 13: 2359-2369. doi: 10.1016/j.nano.2017.06.014
    [135] Zhang F, Trent MJ, Lin YA, et al. (2017) Generation-6 hydroxyl PAMAM dendrimers improve CNS penetration from intravenous administration in a large animal brain injury model. J Control Release 249: 173-182. doi: 10.1016/j.jconrel.2017.01.032
    [136] Balcer LJ, Galetta SL, Calabresi PA, et al. (2007) Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 68: 1299-1304. doi: 10.1212/01.wnl.0000259521.14704.a8
    [137] Sättler MB, Demmer I, Williams SK, et al. (2006) Effects of interferon-beta-1a on neuronal survival under autoimmune inflammatory conditions. Exp Neurol 201: 172-181. doi: 10.1016/j.expneurol.2006.04.015
    [138] Coleman M (2005) Axon degeneration mechanisms: commonality amid diversity. Nat Rev Neurosci 6: 889-898. doi: 10.1038/nrn1788
  • This article has been cited by:

    1. Hua‐Lin Chen, Yi‐Ping Luo, Mu‐Wen Lin, Xiao‐Xia Peng, Mei‐Liang Liu, Yong‐Cun Wang, Shu‐Jun Li, Dong‐Hong Yang, Zhi‐Xiong Yang, Serum exosomal miR ‐16‐5p functions as a tumor inhibitor and a new biomarker for PD‐L1 inhibitor‐dependent immunotherapy in lung adenocarcinoma by regulating PD‐L1 expression , 2022, 11, 2045-7634, 2627, 10.1002/cam4.4638
  • Reader Comments
  • © 2017 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(5889) PDF downloads(1048) Cited by(2)

Figures and Tables

Tables(1)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog